This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD Collaborates With BARDA to Combat Coronavirus Crisis
by Zacks Equity Research
Becton, Dickinson (BDX) forms a strategic public-private partnership with BARDA to help the U.S. government in its efforts to fight the COVID-19 pandemic and future pandemics.
Henry Schein Banks on Dental Consumable Amid Coronavirus Woes
by Zacks Equity Research
Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.
Henry Schein Medical to Expand in Telemedicine With VisualDx
by Zacks Equity Research
Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.
QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results
by Zacks Equity Research
Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.
Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft
by Zacks Equity Research
Baxter (BAX) receives FDA approval for Altapore Shape that will provide surgeons versatile options to advance the art of healing and boost clinical outcomes during a surgery.
Hologic Expands Product Portfolio With New Ultrasound System
by Zacks Equity Research
Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investor confidence is high on Nevro (NVRO), thanks to solid prospects
Medtronic's LINQ II ICM Gets Multiple Regulatory Approvals
by Zacks Equity Research
Medtronic's (MDT) FDA and CE Mark-approved LINQ II ICM enables physicians to optimize device settings via remote programming, without requiring patients' in-office visits.
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
by Zacks Equity Research
Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.
Zacks.com featured highlights include: Sprouts Farmers Market, Patterson Companies, Sleep Number, T-Mobile US and Quest Diagnostics
by Zacks Equity Research
Zacks.com featured highlights include: Sprouts Farmers Market, Patterson Companies, Sleep Number, T-Mobile US and Quest Diagnostics
Medtronic Launches User-Friendly Insulin Infusion Set in US
by Zacks Equity Research
Medtronic's (MDT) MiniMed Mio Advance infusion set, is aimed at providing optimal user experience to insulin pump-using diabetic patients.
LabCorp Launches At-Home Coronavirus Test Collection Kit
by Zacks Equity Research
LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.
BD Receives EUA for New Antigen Test to Combat COVID-19
by Zacks Equity Research
Becton, Dickinson (BDX) receives EUA from the FDA for a rapid, point-of-care, antigen test to detect SARS-CoV-2 in 15 minutes.
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
by Zacks Equity Research
By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
5 Stocks With Relative Price Strength to Enhance Your Returns
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge
by Zacks Equity Research
Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.
Align Technology's Rollouts Aid Amid Procedural Deferrals
by Zacks Equity Research
Align Technology's (ALGN) new virtual solutions ensure continuity of care amid pandemic.
Thermo Fisher Stock Rises on Solid Q2 Growth Expectation
by Zacks Equity Research
Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.
Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis
by Zacks Equity Research
Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.
Pharmaceutical Wholesale to Aid Walgreens' (WBA) Q3 Earnings?
by Zacks Equity Research
Walgreen Boots' (WBA) international businesses in the third quarter is likely to have suffered a huge blow with international trade coming almost to a standstill.
Here's Why You Should Invest in OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to benefit from lucrative prospects in RAYALDEE and BioReference platforms.
Luminex Boosts Product Portfolio With New xMAP Technology
by Zacks Equity Research
Luminex (LMNX) commences rollout of new xMAP INTELLIFLEX Systems, which will expand its xMAP Technology.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.